setmelanotide vs semaglutide Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks Among participants 4 to 66

This review examines the body of evidence for GLP-1 receptor agonists (GLP-1RAs), a class of AOMs relatively frequently used in older adults, focusing on sarcopenia through mechanistic insights and clinical considerations

Long-term data determines whether those results matter

NMRProcFlow: A graphical and interactive tool dedicated to 1D spectra processing for NMR-based metabolomics

Regulatory Peptides , 160 (1-3), 2632

PloS One (2013) 8:e53745

The session used the earliest available published data for CT-388 (24-week interim from ADA/ENDO 2024) and projected a 48-week plateau of 24 to 26% based on trajectory extrapolation from tirzepatide's weight-loss kinetics